PCM-075, a highly-selective adenosine triphosphate competitive inhibitor of the serine/threonine
polo-like-kinase 1 (PLK 1) enzyme that is over-expressed in multiple hematologic and solid tumor cancers, has demonstrated synergy in preclinical studies with over 10 chemotherapeutic and target agents used in hematologic and solid tumor cancers, including FLT3 and HDAC inhibitors, taxanes, and cytotoxins.
PCM-075 is an oral, highly-selective adenosine triphosphate (ATP) competitive inhibitor of the serine/threonine
Polo-like Kinase 1 (PLK1) enzyme, which appears to be over expressed in several different hematologic malignancies and solid tumor cancers.
This protein is a serine/threonine
protein phosphatase that is tightly regulated by [Ca.
According to the company, DB102 (Enzastaurin) is an orally available investigational small molecule, serine/threonine
kinase inhibitor of the PKC beta and AKT pathways and has been studied across solid and hematological tumor types.
found that cantharidin had inhibitory effects on protein serine/threonine
phosphatases (PSPs) of plutella xylostella in vivo and in vitro.
Auxin responsive and transport protein, abscisic acid receptor, serine/threonine
protein kinases and calmodulin were involved in signal transduction under low temperature stress.
2] Nonstandard abbreviations: hsCRP, high-sensitivity C-reactive protein; BRCA1, breast cancer 1; BRCA2, breast cancer 2; HER2, human epidermal growth factor receptor 2; BRAF, B-Raf proto-oncogene, serine/threonine
kinase; JUPITER, Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin.
The MAPKKs in turn phosphorylate the most downstream group of effector serine/threonine
kinases, that is, the MAPKs (Figure 1).
Objective: The mechanistic target of rapamycin (mTOR) is a highly conserved serine/threonine
kinase in eukaryotic organisms.
These include kinase inhibitors with activity against serine/threonine
kinases, dual specificity kinases or both tyrosine and serine/threonine
kinases being developed for oncological indications.
Mutations in serine/threonine
kinase 11 cause Peutz-Jehgers syndrome.
There is a wide range of novel molecular targets distributed among these drug candidates, including growth factors, serine/threonine
protein kinases and tumor associated antigens.